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Abstract
Bone marrow stem cells from diabetes mellitus patients exhibit functional impairment, but the relative molecular
mechanisms responsible for this impairment are poorly understood. We investigated the mechanisms responsible for
diabetes-related functional impairment of bone marrow stem cells by extensively screening the expression levels of
inflammatory factors, cell cycle regulating molecules, extracellular matrix molecules and adhesion molecules. Bone marrow
cells were collected from type 2 diabetic (db/db) and healthy control (db/m+) mice, and c-kit
+ stem cells were purified
(purity.85%) for experiments. Compared with the healthy control mice, diabetic mice had significantly fewer c-kit
+ stem
cells, and these cells had a lower potency of endothelial differentiation; however, the production of the angiogenic growth
factor VEGF did not differ between groups. A pathway-focused array showed that the c-kit
+ stem cells from diabetic mice
had up-regulated expression levels of many inflammatory factors, including Tlr4, Cxcl9, Il9, Tgfb1, Il4, and Tnfsf5, but no
obvious change in the expression levels of cell cycle molecules. Interestingly, diabetes-related alterations of the extracellular
matrix and adhesion molecules were varied; Pecam, Mmp10, Lamc1, Itgb7, Mmp9, and Timp4 were up-regulated, but
Col11a1, Fn1, Admts2, and Itgav were down-regulated. Some of these changes were also confirmed at the protein level by
flow cytometry analysis. In conclusion, c-kit
+ bone marrow stem cells from diabetic mice exhibited an extensive
enhancement of inflammatory factors and disorders of the extracellular matrix and adhesion molecules. Further intervention
studies are required to determine the precise role of each molecule in the diabetes-related functional impairment of c-kit
+
bone marrow stem cells.
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Introduction
In the past decade, a number of studies have demonstrated that
stem cells of bone marrow origin play very important roles in
repairing/regenerating various organs [1–7], including the injured
heart and vessels, through direct regeneration (cell differentiation/
maturation) or indirect mechanisms (paracrine effects) [8–11].
Clinical trials have also attempted to treat ischemic heart diseases
and peripheral arterial diseases by implanting autologous bone
marrow-derived stem cells [12–17]. Some of these clinical trials
have reported improvements in the clinical symptoms and regional
perfusion of ischemia after treatment, but the therapeutic benefits
observed were very marginal and mild, especially in patients of
advanced age and those with diabetes and other diseases.
The inadequate efficiency of stem-cell-based therapy in patients
with advanced age and other complications may be at least
partially associated with the poor quality of cells used for
implantation because aging and diabetes have previously been
demonstrated to decrease the number and impair the function of
bone marrow stem cells [18–22]. Therefore, attenuation of the
impaired function of bone marrow stem cells should be a new
approach to enhance the benefit of stem-cell-based therapy in
these patients.
Our previous study found that oxidative stress likely contributes
to the functional impairment of bone marrow stem cells in type 2
diabetic mice [23], but the precise mechanisms are not clearly
understood. Using a pathway-focused microarray, we extensively
compared the expression levels of inflammatory cytokines, cell
cycle regulating factors, cell adhesion molecules and extracellular
matrix molecules in c-kit
+ bone marrow stem cells from diabetic
mice and normal healthy mice, and we then attempted to further
uncover the complex molecular mechanisms responsible for the
diabetes-associated functional impairment of bone marrow stem
cells.
Materials and Methods
Animals
We used 12-week-old male C57BLKS/J Iar-+Lep
db/+Lep
db
(db/db) mice (SLC, Japan); this mouse strain is characterized by
the spontaneous development of type 2 diabetes mellitus (DM).
C57BLKS/J Iar-m+/+Lep
db (db/m+) mice were used as healthy
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25543controls. We measured the body weight and blood glucose levels of
all mice before sacrifice for the collection and isolation of bone
marrow stem cells. All experiments were approved by were
approved by the Institutional Animal Care and Use Committee of
Yamaguchi University (#2006012), and animal procedures were
performed in accordance with institutional and national guidelines.
Collection, purification, and culture of c-kit
+ bone
marrow stem cells
Bone marrow cells were collected from the femur and tibia, and
mononuclear cells were isolated by density gradient centrifugation.
Stem cells expressing c-kit (c-kit
+) were separated using a magnetic
cellsorting system, as described previously[10,19,23]. Approximately
1.5% (0.86% to 2.12%) of the bone marrow mononuclear cells
expressed c-kit, and the purity of sorted cells was approximately 90%.
Purified c-kit
+ stem cells were seeded on 4-well chamber culture
slides (Nalge Nunc International) coated with 10 mg/ml fibronec-
tin (Invitrogen) at a density of 2610
5 cells/ml in RPMI 1640
medium supplemented with 10% fetal bovine serum (HyClone),
100 units/ml penicillin, and 100 mg/ml streptomycin (Gibco).
Cells were incubated at 37uCi n5 %C O 2 [10,19].
ELISA
To measure the production of growth factors from c-kit
+ stem
cells, the supernatant was collected after 3 days of cell culture and
stored at 280uC. The concentrations of VEGF, bFGF, and IL-1b
in conditioned medium were measured with ELISA kits (R&D
Systems), as described previously [10,19].
Immunocytochemistry
For immunostaining analysis of endothelial differentiation, the cells
were fixed in 1% formaldehyde after 7 days of culture. After blocking
with Protein Block Serum-free (Dako), cells were reacted with
phycoerythrin-conjugated anti-mouse vascular endothelial (VE)-
cadherin antibody (Santa Cruz). Nuclei were stained with 4,6-
diamino-2-phenylindole dihydrochloride (DAPI). The numbers of
positively stained cells were counted under fluorescence microscopy
with 200-fold magnification. Twenty random microscopic fields were
selectedineachchamber,andthemeannumbersofpositivelystained
cells per field were used for statistical analysis [10,19,23].
Gene expression analysis by pathway-focused GEArray
We compared the expression of inflammatory cytokines, cell
cycle regulating factors, cell adhesion molecules and extracellular
matrixmolecules inc-kit
+ bone marrowstem cellsfrom diabetic and
normal healthy mice using signaling pathway-specific gene
expression GEArray systems (SuperArray Bioscience Corporation).
The microarrays were used according to the manufacturer’s
instructions. Briefly, total RNA was extracted from freshly purified
c-kit
+ bone marrow stem cells. Using the reagents provided, cDNA
was prepared from a mixture of purified total RNA of four
independent samples by reverse transcription, biotinylated with
Biotin-16-dUTP (Roche), and then hybridized under precisely
specified conditions to a positively charged nylon membrane
containing the arrayed DNA. The arrays were visualized using a
chemiluminescent detection system (LAS-1000, FUJIFILM). Load-
ing differences were accounted for on the basis of the intensity of the
hybridizationsignals compared to the housekeepinggenes,and then
gene expression was quantified by scanning densitometry [24].
Flow cytometry
To confirm the expression levels of genes observed using the
pathway-focused GEArray at the protein level, we collected
mononuclear cells from mice. Cells were blocked with 0.5% BSA
for 10 min and labeled with FITC-conjugated anti-mouse c-kit
+
antibody for 30 min. After washing, cells were then incubated with
antibodies against TNFR2, TLR4, integrin-av, PECAM-1, fibro-
nectin, or laminin (BD Bioscience). Respective isotype controls were
used as a negative control. Quantitative flow cytometry analysis was
performed using a FACSCalibur (Becton Dickinson) [7,21].
Statistical analysis
All results are presented as the mean 6 SD. Statistical
significance between two groups was determined using the 2-
tailed unpaired t-test (Dr. SPSS II, Chicago, IL). Differences were
considered significant when p,0.05.
Results
Diabetes decreased the number and impaired the
function of c-kit
+ bone marrow stem cells
When compared with healthy mice, the db/db diabetic mice had
significantly higher body weights (p,0.05, Figure 1A)a n db l o o d
glucose levels (p,0.001, Figure 1B), confirming that these mice had
early-stage type 2 diabetes mellitus (body weight loss at late-stage in
these obesity type 2 diabetes mice). Although all procedures of cell
collection and isolation were performed in the same way, significantly
fewer bone marrow mononuclear cells were collected from diabetic
mice than from healthy mice (p,0.05, Figure 1C). Furthermore, the
subpopulation of c-kit
+ stem cells in freshly collected bone marrow
mononuclear cells was also significantly smaller in diabetic mice than
that from healthy control mice (p,0.05, Figure 1D).
After 7 days of culturing purified c-kit
+ stem cells, we found that
cells from diabetic mice had poorer attachment and expressed
lower levels of VE-cadherin when compared with cells from
healthy control mice (p,0.05, Figure 1E). However, the production
of VEGF from c-kit
+ stem cells did not differ significantly between
groups at 3 days after culture (p=0.31, Figure 1F), in agreement
with the results of our recent study using bone marrow
mononuclear cells from diabetic patients [25]. The production
of bFGF and IL-1b was not detectable by ELISA.
Diabetes increased the expression of inflammatory-
related factors in c-kit
+ bone marrow stem cells
We compared the expression levels of inflammatory-related
factors in freshly purified c-kit
+ stem cells between diabetic and
healthy control mice. Among the 84 genes included in the pathway-
focused GEArray system, 25 genes were up-regulated more than 2-
fold in diabetic mice when compared with healthy control mice
(Figure 2). These genes included Tlr4, Cxcl9, Il9, Tgfb1, Il4, ccl19,
Il11,a n dTnfsf5. No inflammatory-related gene was down-regulated
more than 2-fold in the c-kit
+ stem cells of diabetic mice.
Furthermore, we confirmed some of the GEArray data at the
protein level using flow cytometry analysis. Only approximately
4.5% of c-kit
+ stem cells from healthy control mice positively
expressed TNF receptor 2, but the expression of this protein was
observed in approximately 15% of c-kit
+ stem cells from diabetic
mice (p,0.01, Figure 3A). Similarly, the expression of toll-like
receptor 4 was observed in approximately 20% of c-kit
+ stem cells
from diabetic mice but in only 5% of those from healthy control
mice (p,0.01, Figure 3B).
Diabetes did not change the cell cycle-related factors in
c-kit
+ bone marrow stem cells
The expression of cell cycle-related factors in c-kit
+ stem cells
was also compared between diabetic and healthy control mice.
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25543Figure 1. Differences in number and function of bone marrow stem cells between diabetic and healthy mice. Compared with healthy
control mice, diabetic mice had significantly lower body weights (A) and higher blood glucose levels (B). Significantly fewer total bone marrow
mononuclear cells were harvested from diabetic mice than from healthy control mice (C), and the subpopulation of c-kit+ stem cells was significantly
decreased in diabetic mice (D). After 7 days of culture, the c-kit+ stem cells from diabetic mice showed significantly less differentiation into VE-
cadherin-positive endothelial cells than did cells from healthy control mice (E), but the production of VEGF did not differ between the two groups (F).
doi:10.1371/journal.pone.0025543.g001
Figure 2. Pathway-focused GEArray analysis of the expression of inflammatory-related factors. Compared with the healthy control mice,
the expression of inflammatory-related genes was extensively up-regulated in the c-kit+ bone marrow stem cells from diabetic mice.
doi:10.1371/journal.pone.0025543.g002
Diabetes Impairs Bone Marrow Stem Cells
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25543Although many of the cell cycle genes were clearly detected by the
GEArray system (Figure 4), only two genes, Pes1 and Itgb1, were
changed (down-regulation) more than 2-fold (2.2- and 2.3-fold,
respectively) in diabetic mice when compared with healthy control
mice (Figure 4). Itgb1 is a well-known cell adhesion molecule, and
we will discuss the data for this protein in detail below.
Diabetes induced varying changes in the expression
levels of ECM and adhesion molecules in c-kit
+ bone
marrow stem cells
Interestingly, diabetes induced varying changes in the expres-
sion of ECM and cell adhesion molecules in c-kit
+ stem cells.
Among the 84 genes included in the GEArray system, 10 genes
(MMP10, Pecam1, MMP9, Timp2, Lamc1, Mmp24, Mmp2, Mmp14,
Itgb7, and Timp4) were up-regulated, and 9 genes (Col11a1, Fn1,
Adamts2, Itgav, Col6a2, Itga2b, Col4a3, Col18a1, and Ecm1) were
down-regulated more than 1.5-fold in diabetic mice when
compared with those from healthy controls (Figure 5).
Furthermore, we examined some of these changes at the protein
level using flow cytometry analysis. We confirmed that the
expression of one important cell adhesion molecule, integrin-av,
was significantly decreased (p,0.01, Figure 6A), but the expression
of another important cell adhesion molecule, Pcam-1, was
increased (p,0.01, Figure 6B) in c-kit
+ stem cells from diabetic
mice when compared with healthy controls.
Similarly, diabetes induced varying changes in ECM protein
expression in c-kit
+ bone marrow stem cells. One important ECM
protein, fibronectin, was significantly decreased (p,0.01, Figure 7A),
but laminin, another important ECM protein, was increased
(p,0.01, Figure 7B) in c-kit
+ stem cells from diabetic mice when
compared with healthy controls.
Discussion
Diabetes is well known to induce renal failure, impair
hematopoiesis, and increase the risk of cardiovascular diseases
[26,27], but the precise mechanisms responsible for these diabetes-
associated complications are not understood. In addition to
hematogenesis, increased evidence has shown that bone marrow
stem cells likely play important roles in repairing various tissues/
organs [1–7]. Therefore, the reduced number and impaired
function of bone marrow stem cells may contribute to the
development of many complications. If we can understand the
molecular mechanisms associated with the functional impairment
of bone marrow stem cells, new approaches may be found to
prevent and treat these diabetes-associated complications.
In this study, we purified c-kit
+ bone marrow stem cells from
early-stage diabetic mice (12 weeks old) for analysis and confirmed
that diabetes is associated with a decrease in the number of c-kit
+
bone marrow stem cells and that diabetes partially impairs their
endothelial differentiation function [18–23].
Using a screening analysis of three of the most interesting
pathways in this study, we obtained several interesting findings.
First, the extensive enhancement of inflammatory factors in c-kit
+
bone marrow stem cells from diabetic mice supported our
speculation that systemic and local inflammatory microenviron-
ments play central roles in the decrease in the number and
functions of bone marrow cells. In fact, diabetes is considered an
inflammatory disease that is characterized by increases in
oxidative stress (e.g., the oxidation of glucose) and advanced
glycation end-products (AGE) [23,28], which induce the up-
regulation of many inflammatory cytokines, such as MCP-1, TNF-
a, IL-1, and IL-6 [29,30]. We found that expressions of TNF
receptor 2 and toll-like receptor 4 were significantly increased in
these c-kit
+ bone marrow stem cells from diabetic mice. Although
it has reported that TNF receptor 2 is required for angiogenesis in
response to ischemia [31], TNF receptors as mediators of
apoptosis have been classically considered as negative regulators
in the immune and hematopoietic systems to suppress hemato-
poietic stem and progenitor cell function [32]. Toll-like receptor 4
is primarily identified as an innate immune receptor, but it has
been recently found to play a negative role in stem cells [33,34].
Although further intervention experiments are required to identify
the key mediators and the pathway signaling in detail, inflamma-
tory stimulation likely contributes to the functional impairment of
bone marrow stem cells in diabetes patients.
Because the number of c-kit
+ bone marrow stem cells was
decreased in diabetic mice, the proliferative activity of stem cells
Figure 3. Expression of tumor necrosis factor receptor 2 (TNFR2) and toll-like receptor 4 (TLR4) in bone marrow stem cells. Flow
cytometry analysis showed that the positive expression levels of TNFR2 and TLR4 in the c-kit+ bone marrow stem cells from diabetic mice were
significantly higher (.3-fold) than in cells from healthy control mice.
doi:10.1371/journal.pone.0025543.g003
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[35,36]. However, the expression levels of cell cycle-related factors
in c-kit
+ bone marrow stem cells did not obviously change between
diabetic and healthy control mice. This result may due to that fact
that the cells used for analysis were harvested at the early-stage of
diabetes, at which the number of stem cells in the bone marrow
may not have dramatically decreased. Alternatively, the prolifer-
ative activity of bone marrow stem cells in diabetic mice may be
suppressed by the inflammatory microenvironment or other
unknown mechanisms.
The pattern of changes in the expression levels of ECM and
adhesion molecules was quite interesting. As inflammation is
known to change the expression of ECM and adhesion molecules
in various types of cells, it is not difficult to conjecture that the
systemic and local inflammatory microenvironment of diabetes
may induce these changes in the expression levels of bone marrow
Figure 4. Pathway-focused GEArray analysis of cell cycle-related factors. The expression of cell cycle-related genes was clearly detected in
the c-kit+ bone marrow stem cells from both diabetic mice and healthy control mice. However, the difference observed in the expression levels
between groups was very mild (,2-fold).
doi:10.1371/journal.pone.0025543.g004
Figure 5. Pathway-focused GEArray analysis of the gene expression of extracellular matrix and adhesion molecules. Compared with
the healthy control mice, 10 genes were up-regulated and 9 genes were down-regulated in the c-kit+ bone marrow stem cells from the diabetic mice.
doi:10.1371/journal.pone.0025543.g005
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expression levels of ECM and adhesion molecules. However,
approximately half of these ECM and adhesion molecules were
down-regulated in bone marrow stem cells of diabetic mice. Thus,
the mechanism responsible for the diabetes-induced disorder of
ECM and adhesion molecules in bone marrow stem cells is not
Figure 6. Expression of the adhesion molecules integrin-av and Pecam-1 in bone marrow stem cells. Flow cytometry analysis showed
that the expression of integrin-av (A) was decreased but that of Pecam-1 (B) was increased in the c-kit+ bone marrow stem cells from diabetic mice
when compared with those from healthy control mice.
doi:10.1371/journal.pone.0025543.g006
Figure 7. Expression of the extracellular matrix molecules fibronectin and laminin in bone marrow stem cells. Flow cytometry analysis
showed that the expression of fibronectin (A) was decreased but that of laminin (B) was increased in the c-kit+ bone marrow stem cells from diabetic
mice when compared with cells from healthy control mice.
doi:10.1371/journal.pone.0025543.g007
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of Itgb1 was detected in the stem cells of diabetic mice (Figure 4).
This result agreed well with results of our previous study that
functional impairment of ex vivo expanded bone marrow stem cells
was related to decreased expression of integrin-b1 [37]. Although
the ECM and adhesion molecules are generally known to be
critical for cell growth, it is poorly understood on their precise role
in regulating the growth and differentiation of stem cells. In this
study, we found that the expression of integrin av was decreased in
these c-kit
+ bone marrow stem cells from diabetic mice. Agree well
with our data, it has been demonstrated that oxidized low density
lipoprotein induce functional impair of endothelial progenitor cell
by down-regulation of E-selectin and integrin avb5 [38]. However,
it has reported that the av subunit of integrin does not appear to be
involved with the attachment of embryonic stem cells to
fibronectin [39]. An interventional approach of inflammatory
inhibition will help us to demonstrate the causal relationship
between inflammation and the disorder of ECM and adhesion
molecules.
Several limitations of this study need to be mentioned. First, we
detected extensive changes in the expression levels of many
inflammatory factors, ECM molecules, and adhesion molecules,
but we did not identify the factor(s) that would be critical to induce
the functional impairment of bone marrow stem cells. Second, we
only screened three pathways in this study, but diabetes may also
induce changes in many other pathways that contribute to the
functional impairment of bone marrow stem cells. Further in vitro
and in vivo studies will be needed to elucidate how these changes
affect the growth and function of bone marrow stem cells.
In summary, c-kit
+ bone marrow stem cells from diabetic mice
exhibited extensive enhancement of inflammatory factors and
changes in the expression of ECM and adhesion molecules, which
might contribute to the decrease in the number of bone marrow
stem cells and the impairment of their function for endothelial
differentiation. The identification of key factor(s) in future studies
will enable us to find novel approaches to prevent or reverse the
diabetes-related functional impairment of stem cells.
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